Detalles de la búsqueda
1.
Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
J Am Acad Dermatol
; 86(3): 581-589, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34252464
2.
Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study.
J Drugs Dermatol
; 21(4): 399-407, 2022 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35389589
3.
Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
J Am Acad Dermatol
; 82(4): 927-935, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31712178
4.
Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.
J Oncol Pharm Pract
; 25(4): 855-864, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29661050
5.
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
BMC Womens Health
; 13: 15, 2013 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-23521803
6.
Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA.
Clin Drug Investig
; 43(3): 185-196, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36840815
7.
Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months.
Pharmacoecon Open
; 6(6): 871-880, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36155891
8.
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings.
J Med Econ
; 25(1): 741-749, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35615978
9.
Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months.
Dermatol Ther (Heidelb)
; 11(6): 2133-2145, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652590
10.
Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab.
Patient Prefer Adherence
; 14: 517-527, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32210539
11.
Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Oncology
; 77(3-4): 244-53, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19738390
12.
Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
Curr Med Res Opin
; 35(3): 513-523, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30286662
13.
Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
J Manag Care Spec Pharm
; 25(12): 1366-1376, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31778621
14.
Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
J Manag Care Spec Pharm
; 24(1): 47-55, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29290171
15.
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis
; 24(9): 1876-1882, 2018 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-29668916
16.
Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes.
Clin Ther
; 29(10): 2246-55, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18042482
17.
Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis.
J Med Econ
; 20(9): 982-990, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28635342
18.
Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics.
Curr Med Res Opin
; 31(2): 275-88, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25365467
19.
Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents.
Int J Breast Cancer
; 2014: 475171, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25180099
20.
Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
Semin Arthritis Rheum
; 43(1): 39-47, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23453683